Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
In the latest trading session, Analog Devices (ADI) closed at $235.5, marking a -2.07% move from the previous day.
Investors need to pay close attention to ADI stock based on the movements in the options market lately.
Analog Devices (ADI) reached $240.37 at the closing of the latest trading day, reflecting a -1.27% change compared to its last close.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Analog Devices (ADI) closed at $245.15 in the latest trading session, marking a +1.38% move from the prior day.
Analog Devices (ADI) reached $245.15 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.
After reaching an important support level, Analog Devices, Inc. (ADI) could be a good stock pick from a technical perspective. ADI recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
The latest trading day saw Analog Devices (ADI) settling at $237.33, representing a +1.13% change from its previous close.
Analysts expect SMTC and ADI to see strong double-digit growth in 2025, despite the negative macro and geopolitics plaguing the Analog/Mixed Signal semiconductor industry.
Analog Devices, Inc. (NASDAQ:ADI ) Bernstein 41st Annual Strategic Decisions Conference May 29, 2025 11:00 AM ET Company Participants Rich Puccio - CFO Conference Call Participants Stacy Rasgon - Bernstein Stacy Rasgon I'm Stacy Rasgon. I cover the US semiconductor sector here at Bernstein.
Analog Devices excels in high-performance analog and mixed-signal ICs, boasting strong R&D, diversified markets, and industry-leading profitability. Despite a 2024 downturn, ADI maintained high margins, robust free cash flow, and raised its dividend, signaling management confidence in future growth. My DCF analysis values ADI at $304.12 per share, highlighting significant undervaluation and strong long-term upside for patient investors.